Published in Blood on July 31, 2008
Pethema Multiple Myeloma 2000 | NCT00560053
Multiple Myeloma Molecular Monitoring Study (M4) | NCT03421132
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood (2014) 2.25
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res (2013) 1.72
The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia (2009) 1.33
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Curing myeloma at last: defining criteria and providing the evidence. Blood (2014) 1.30
European perspective on multiple myeloma treatment strategies in 2014. Oncologist (2014) 1.28
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood (2015) 1.23
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia (2013) 1.08
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica (2009) 1.08
Minimal residual disease in multiple myeloma. J Clin Oncol (2013) 1.01
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia (2014) 1.00
The future of autologous stem cell transplantation in myeloma. Blood (2014) 0.99
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica (2010) 0.90
Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant (2015) 0.88
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood (2014) 0.87
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res (2013) 0.86
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica (2015) 0.86
Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol (2012) 0.85
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget (2015) 0.85
The current status of minimal residual disease assessment in myeloma. Leukemia (2014) 0.83
Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma. Oncologist (2013) 0.83
Flow cytometry and laser scanning cytometry, a comparison of techniques. J Clin Monit Comput (2010) 0.83
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients. J Korean Med Sci (2013) 0.82
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica (2014) 0.82
Pursuing the curative blueprint for early myeloma. Blood (2013) 0.81
Going with the flow, and beyond, in myeloma. Blood (2008) 0.81
Dilemmas in treating smoldering multiple myeloma. J Clin Oncol (2014) 0.81
How best to use new therapies in multiple myeloma. Blood Rev (2010) 0.81
Staging and prognostication of multiple myeloma. Expert Rev Hematol (2014) 0.81
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. Adv Hematol (2014) 0.81
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget (2012) 0.80
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. Br J Haematol (2016) 0.80
In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival. Mol Cancer (2012) 0.79
Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. Clin Chem (2015) 0.79
Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med (2014) 0.79
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant (2016) 0.78
Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica (2009) 0.78
Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol (2013) 0.78
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2016) 0.77
Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation. Biomed Res Int (2014) 0.76
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother (2015) 0.76
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. J Exp Clin Cancer Res (2016) 0.76
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. J Transl Med (2015) 0.76
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep (2016) 0.75
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. Korean J Intern Med (2016) 0.75
Maintenance therapy in multiple myeloma. Ther Adv Hematol (2016) 0.75
Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplant (2015) 0.75
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther (2017) 0.75
Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci (2016) 0.75
Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. J Clin Diagn Res (2016) 0.75
Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation. ISRN Hematol (2013) 0.75
Novel drugs for the treatment of multiple myeloma. Haematologica (2010) 0.75
Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma. Mediterr J Hematol Infect Dis (2012) 0.75
The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China. Kidney Dis (Basel) (2016) 0.75
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica (2014) 0.75
Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry B Clin Cytom (2015) 0.75
Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology (2016) 0.75
Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities. Oncol Rev (2012) 0.75
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget (2016) 0.75
The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol (2017) 0.75
MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients. Bone Marrow Transplant (2016) 0.75
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica (2017) 0.75
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. J Cancer Res Clin Oncol (2016) 0.75
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol (2017) 0.75
Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis. PLoS One (2017) 0.75
Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leuk Lymphoma (2016) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol (1998) 3.41
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica (2005) 2.87
Phenotypic difference of normal plasma cells from mature myeloma cells. Blood (1993) 2.35
High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol (1999) 1.84
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica (2007) 1.59
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma (2008) 1.57
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res (2006) 1.52
Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood (1997) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 1.22
Conventional diagnostics in multiple myeloma. Eur J Cancer (2006) 1.20
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood (1999) 1.20
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood (2000) 1.10
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood (2003) 1.06
Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol (1996) 0.99
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res (2005) 0.97
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet (1992) 0.95
Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med (2005) 0.93
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol (2001) 0.92
Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol (2002) 0.91
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica (2000) 0.87
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica (1999) 0.86
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica (2005) 2.87
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood (2011) 2.58
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood (2006) 2.51
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica (2008) 2.32
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer (2009) 2.12
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica (2002) 2.08
Incidence of Wra antigen and anti-Wra in a Spanish population. Transfusion (2005) 2.05
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leuk Lymphoma (2011) 2.04
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol (2015) 2.03
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. Med Clin (Barc) (2012) 2.02
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood (2003) 1.70
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol (2013) 1.70
Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica (2007) 1.68
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma (2006) 1.65
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy (2009) 1.60
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2008) 1.57